Suppr超能文献

多种化合物抑制 KDM5A 组蛋白赖氨酸去甲基酶的结构基础。

Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.

机构信息

Department of Biochemistry, Emory University, Atlanta, GA 30322, USA.

Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.

出版信息

Cell Chem Biol. 2016 Jul 21;23(7):769-781. doi: 10.1016/j.chembiol.2016.06.006. Epub 2016 Jul 14.

Abstract

The KDM5/JARID1 family of Fe(II)- and α-ketoglutarate-dependent demethylases removes methyl groups from methylated lysine 4 of histone H3. Accumulating evidence supports a role for KDM5 family members as oncogenic drivers. We compare the in vitro inhibitory properties and binding affinity of ten diverse compounds with all four family members, and present the crystal structures of the KDM5A-linked Jumonji domain in complex with eight of these inhibitors in the presence of Mn(II). All eight inhibitors structurally examined occupy the binding site of α-ketoglutarate, but differ in their specific binding interactions, including the number of ligands involved in metal coordination. We also observed inhibitor-induced conformational changes in KDM5A, particularly those residues involved in the binding of α-ketoglutarate, the anticipated peptide substrate, and intramolecular interactions. We discuss how particular chemical moieties contribute to inhibitor potency and suggest strategies that might be utilized in the successful design of selective and potent epigenetic inhibitors.

摘要

KDM5/JARID1 家族的 Fe(II)和α-酮戊二酸依赖性去甲基酶将组蛋白 H3 赖氨酸 4 上的甲基基团去除。越来越多的证据支持 KDM5 家族成员作为致癌驱动因子的作用。我们比较了十种不同化合物对所有四个家族成员的体外抑制特性和结合亲和力,并展示了 KDM5A 连接的 Jumonji 结构域在 Mn(II)存在下与其中八种抑制剂结合的晶体结构。所有八种结构上经过检查的抑制剂都占据了α-酮戊二酸的结合位点,但在其特定的结合相互作用上有所不同,包括参与金属配位的配体数量。我们还观察到 KDM5A 中的抑制剂诱导构象变化,特别是那些涉及α-酮戊二酸、预期的肽底物以及分子内相互作用的残基。我们讨论了特定的化学部分如何有助于抑制剂的效力,并提出了可能用于成功设计选择性和有效的表观遗传抑制剂的策略。

相似文献

1
Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Cell Chem Biol. 2016 Jul 21;23(7):769-781. doi: 10.1016/j.chembiol.2016.06.006. Epub 2016 Jul 14.
2
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
J Biol Chem. 2016 Feb 5;291(6):2631-46. doi: 10.1074/jbc.M115.698449. Epub 2015 Dec 8.
3
Structure-based design and discovery of potent and selective KDM5 inhibitors.
Bioorg Med Chem Lett. 2018 May 15;28(9):1490-1494. doi: 10.1016/j.bmcl.2018.03.083. Epub 2018 Mar 30.
4
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
J Med Chem. 2018 Dec 13;61(23):10588-10601. doi: 10.1021/acs.jmedchem.8b01219. Epub 2018 Nov 15.
5
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Bioorg Med Chem. 2019 Mar 15;27(6):1119-1129. doi: 10.1016/j.bmc.2019.02.006. Epub 2019 Feb 4.
6
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Nat Chem Biol. 2016 Jul;12(7):531-8. doi: 10.1038/nchembio.2085. Epub 2016 May 23.
7
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Bioorg Med Chem Lett. 2019 May 15;29(10):1173-1176. doi: 10.1016/j.bmcl.2019.03.028. Epub 2019 Mar 21.
8
Identification of potent, selective KDM5 inhibitors.
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4350-4. doi: 10.1016/j.bmcl.2016.07.026. Epub 2016 Jul 19.
9
Pharmacological inhibition of KDM5A for cancer treatment.
Eur J Med Chem. 2021 Dec 15;226:113855. doi: 10.1016/j.ejmech.2021.113855. Epub 2021 Sep 15.
10
The KDM5 family of histone demethylases as targets in oncology drug discovery.
Epigenomics. 2014 Jun;6(3):277-86. doi: 10.2217/epi.14.14.

引用本文的文献

1
L-2-hydroxyglutarate impairs neuronal differentiation through epigenetic activation of expression.
bioRxiv. 2025 Jun 24:2025.04.16.649033. doi: 10.1101/2025.04.16.649033.
2
Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.
Front Pharmacol. 2025 Feb 17;16:1504618. doi: 10.3389/fphar.2025.1504618. eCollection 2025.
3
Current advances and future directions in targeting histone demethylases for cancer therapy.
Mol Cells. 2025 Mar;48(3):100192. doi: 10.1016/j.mocell.2025.100192. Epub 2025 Feb 10.
4
Pharmacological agents targeting drug-tolerant persister cells in cancer.
Pharmacol Res. 2024 May;203:107163. doi: 10.1016/j.phrs.2024.107163. Epub 2024 Apr 1.
5
Identifying ligands for the PHD1 finger of KDM5A through high-throughput screening.
RSC Chem Biol. 2023 Dec 18;5(3):209-215. doi: 10.1039/d3cb00214d. eCollection 2024 Mar 6.
6
Gene Regulation and Mitochondrial Activity During White and Brown Adipogenesis Are Modulated by KDM5 Histone Demethylase.
J Endocr Soc. 2024 Feb 13;8(4):bvae029. doi: 10.1210/jendso/bvae029. eCollection 2024 Feb 19.
8
Recent developments in catalysis and inhibition of the Jumonji histone demethylases.
Curr Opin Struct Biol. 2023 Dec;83:102707. doi: 10.1016/j.sbi.2023.102707. Epub 2023 Oct 11.
9
KDM5 Lysine Demethylases in Pathogenesis, from Basic Science Discovery to the Clinic.
Adv Exp Med Biol. 2023;1433:113-137. doi: 10.1007/978-3-031-38176-8_6.
10

本文引用的文献

1
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
J Med Chem. 2016 Feb 25;59(4):1370-87. doi: 10.1021/acs.jmedchem.5b01538. Epub 2016 Jan 15.
2
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
J Med Chem. 2016 Feb 25;59(4):1357-69. doi: 10.1021/acs.jmedchem.5b01537. Epub 2016 Jan 15.
4
Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
J Biol Chem. 2016 Feb 5;291(6):2631-46. doi: 10.1074/jbc.M115.698449. Epub 2015 Dec 8.
5
Catalytic Mechanisms of Fe(II)- and 2-Oxoglutarate-dependent Oxygenases.
J Biol Chem. 2015 Aug 21;290(34):20702-20711. doi: 10.1074/jbc.R115.648691. Epub 2015 Jul 7.
6
A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Med Res Rev. 2015 Sep;35(5):1032-71. doi: 10.1002/med.21350. Epub 2015 May 19.
8
Structural definitions of Jumonji family demethylase selectivity.
Drug Discov Today. 2015 Jun;20(6):743-9. doi: 10.1016/j.drudis.2014.12.013. Epub 2014 Dec 31.
9
Inhibition of demethylases by GSK-J1/J4.
Nature. 2014 Oct 2;514(7520):E1-2. doi: 10.1038/nature13688.
10
Regulation of histone H3K4 methylation in brain development and disease.
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 26;369(1652). doi: 10.1098/rstb.2013.0514.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验